Plain-English translation of NCT07069699 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called to treat aggressive types of lymphoma (a blood cancer) that have specific changes in genes called MYC, BCL2, or BCL6. The medication works by targeting cancer cells with these genetic changes. Researchers want to find the right dose of the treatment and see how well it works for patients whose cancer has not responded to previous therapies.
Patients with these aggressive lymphomas often run out of effective treatment options after trying multiple standard therapies. This medication targets the specific genetic changes that drive these cancers, offering hope for people who need new options.
You likely qualify if…
You likely don't qualify if…
You would receive the medication as an intravenous infusion (through an IV) twice per cycle—on day 1 and day 8—with each cycle lasting 3 weeks. You would continue treatment as long as it is working and you are tolerating it well. Throughout the study, you would have regular blood tests, imaging scans (CT and PET scans), and possibly a spinal tap to collect fluid; you would also have a tumor biopsy. After treatment ends, you would return for follow-up visits at 30 days, then every 3–4 months for the first 2 years, and then every 6 months for years 3–5.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
United States